Literature DB >> 11409142

Management of rheumatoid arthritis: the historical context.

L W Moreland1, A S Russell, H E Paulus.   

Abstract

We review the historical highlights of the management of rheumatoid arthritis (RA). Studies of nonsteroidal antiinflammatory drugs, disease modifying antirheumatic drugs, and biological agents over 5 decades were evaluated and summarized. There is emphasis on drug therapy as it has developed and evolved from empirical relief of symptoms with salicylates to targeted intervention in the immunoinflammatory process with tumor necrosis factor inhibitors. A therapeutic paradigm has been proposed to rationalize the use of the available therapies. If one accepts the thesis that both the acute and chronic consequences of RA are due to persistent misdirected and inadequately controlled inflammation that causes tissue destruction and loss of function, then prolonged complete control of the abnormal inflammatory process is the fundamental first step in the management of all patients with RA. Unfortunately, even with the newest therapeutic options to treat RA, most patients achieve only partial suppression of inflammation and many lose therapeutic benefit after an initial good response. The management of persistent or recurrent rheumatoid inflammation and disability continues to be a challenge. It remains to be determined whether the future addition of more potent specific interventions in the immunoinflammatory process will be able to solve this problem without disarming host defenses against infections and tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409142

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

2.  New Therapies for Rheumatoid Arthritis.

Authors:  A Kumar; V Marwaha
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Ankylosing spondylitis: an overview.

Authors:  J Sieper; J Braun; M Rudwaleit; A Boonen; A Zink
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

4.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.

Authors:  J Fransen; H Bernelot Moens; I Speyer; P L C M van Riel
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 5.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial.

Authors:  J Fransen; G Stucki; J Twisk; A-M Chamot; J-C Gerster; T Langenegger; M Seitz; B A Michel
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

7.  Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study.

Authors:  Minh Nguyen; Marmar Kabir; Philippe Ravaud
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Is three selected parameters adequate to monitor rheumatoid arthritis?

Authors:  S Chandrashekara; M Syed; R Swapna
Journal:  Clin Rheumatol       Date:  2006-10-07       Impact factor: 3.650

9.  Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor.

Authors:  Hana Maizuliana Bt Solehan; Mohd Shahrir Mohamed Said; Sazliyana Shaharir; Sakthiswary Rajalingham
Journal:  J Clin Med Res       Date:  2011-09-26

Review 10.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.